MedTrace Logo

Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients

NCT03173859 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-11-18

No results posted yet for this study

Summary

A randomized phase II study comparing the sequential use of abiraterone followed after progression by apalutamide with alternating cycles of abiraterone and apalutamide

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG

Abiraterone

Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally

DRUG

Apalutamide

apalutamide 240mg qD orally

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03173859 on ClinicalTrials.gov